Moreover, in a recent phase 2 trial, the JAK1/JAK2 inhibitor momelotinib has shown efficacy in the anemia of MF [21] and a phase 3 trial comparing this drug with danazol is currently in progress. This evidence concerns the gene JAK1 and anemia.